SCHEMBL3422707

SCHEMBL3422707

C/C=C\c1cc([N+](=O)[O-])ccc1-n1cccc(O)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.42
ALDH1A1 P00352 7/20 0.40
MEN1 O00255 7/20 0.40
KMT2A Q03164 7/20 0.40
MAPT P10636 7/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
GAA P10253 3/20 0.40
HPGD P15428 2/20 0.39
POLB P06746 4/20 0.39
HTT P42858 3/20 0.37
LMNA P02545 2/20 0.37
HCRTR1 O43613 1/20 0.37
BAX Q07812 2/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 2/20 0.37
XBP1 P17861 1/20 0.36
CASP1 P29466 1/20 0.36
CASP3 P42574 1/20 0.36
CASP4 P49662 1/20 0.36
CASP7 P55210 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3422710 1.00 ERN1 (0.42) ERN1ALDH1A1MEN1KMT2AMAPT
SCHEMBL13272461 1.00 ERN1 (0.42) ERN1ALDH1A1MEN1KMT2AMAPT
SCHEMBL3060321 0.86 CHEK1 (0.38) ERN1ALDH1A1MEN1KMT2AMAPT
SCHEMBL2477838 0.86 CHEK1 (0.38) ERN1ALDH1A1MEN1KMT2AMAPT
SCHEMBL13896885 0.85 ERN1 (0.43) ERN1ALDH1A1MEN1KMT2AMAPT
SCHEMBL2474270 0.85 NR1H2 (0.36) ERN1ALDH1A1MEN1KMT2AMAPT
SCHEMBL2474273 0.85 NR1H2 (0.36) ERN1ALDH1A1MEN1KMT2AMAPT
SCHEMBL2477437 0.84 TSHR (0.38) ERN1ALDH1A1MEN1KMT2AMAPT
SCHEMBL2477436 0.84 TSHR (0.38) ERN1ALDH1A1MEN1KMT2AMAPT
SCHEMBL3419892 0.84 MAPT (0.43) ALDH1A1MEN1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-8383822-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-26 US disclosed
EP-2170877-B1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION BAYER IP GMBH (DE) 2012-11-21 EP disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L ERN1 4663/4885ALDH1A1 523/4885MEN1 1705/4885
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L ERN1 4663/4885ALDH1A1 523/4885MEN1 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.